Fructose and sugar: A major mediator of non-alcoholic fatty liver disease

Journal of Hepatology

Volumn 68, Issue 5, 2018, Pages 1063-1075

  Jensen, Thomas ^a   Abdelmalek, Manal F ^b   Sullivan, Shelby ^a   Nadeau, Kristen J ^c   Green, Melanie ^c   Roncal, Carlos ^a   Nakagawa, Takahiko ^d   Kuwabara, Masanari ^a   Sato, Yuka ^a   Kang, Duk Hee ^e   Tolan, Dean R ^f   Sanchez Lozada, Laura G ^g   Rosen, Hugo R ^a   Lanaspa, Miguel A ^a   Diehl, Anna Mae ^b   Johnson, Richard J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

^d NARA MEDICAL UNIVERSITY   (Japan)

^e Ewha Womans University School of Medicine   (South Korea)

^f USA   (United States)

^g Laboratory of Renal Physiopathology and Department of Nephrology   (Mexico)

Author keywords

Hepatic inflammation; Hepatic steatosis; Insulin resistance; Sugar consumption; Uric acid

Indexed keywords

FRUCTOKINASE; FRUCTOSE; SUGAR; URIC ACID; CARBOHYDRATE; CORN SYRUP; GLUCOSE;

CLINICAL STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; EXPERIMENTAL STUDY; FATTY ACID OXIDATION; FRUCTOSE METABOLISM; GLUCOSE METABOLISM; HUMAN; IMMUNE SYSTEM; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; LIPID STORAGE; LIPOGENESIS; LIVER PROTECTION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SOFT DRINK; SUGAR INTAKE; SUGAR-SWEETENED BEVERAGE; URIC ACID BLOOD LEVEL; ADVERSE EVENT; ANIMAL; BEVERAGE; CARBONATED BEVERAGE; EATING; LIPID METABOLISM; METABOLISM; OXIDATION REDUCTION REACTION;

ANIMALS; BEVERAGES; CARBONATED BEVERAGES; EATING; FRUCTOKINASES; FRUCTOSE; GASTROINTESTINAL MICROBIOME; GLUCOSE; HIGH FRUCTOSE CORN SYRUP; HUMANS; LIPID METABOLISM; LIPOGENESIS; NON-ALCOHOLIC FATTY LIVER DISEASE; OXIDATION-REDUCTION; RISK FACTORS; SUGARS; URIC ACID;

EID: 85042418281     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2018.01.019     Document Type: Review

References (165)

1. Saab, K.R., Kendrick, J., Yracheta, J.M., Lanaspa, M.A., Pollard, M., Johnson, R.J., New insights on the risk for cardiovascular disease in african Americans: the role of added sugars. J Am Soc Nephrol, 2014.
2. Yracheta, J.M., Alfonso, J., Lanaspa, M.A., Roncal-Jimenez, C., Johnson, S.B., Sanchez-Lozada, L.G., et al. Hispanic Americans living in the United States and their risk for obesity, diabetes and kidney disease: Genetic and environmental considerations. Postgrad Med 127 (2015), 503–510.
3. Yracheta, J.M., Lanaspa, M.A., Le, M.T., Abdelmalak, M.F., Alfonso, J., Sanchez-Lozada, L.G., et al. Diabetes and kidney disease in american indians: potential role of sugar-sweetened beverages. Mayo Clin Proc 90 (2015), 813–823.
4. Johnson, R.J., Lanaspa, M.A., Sanchez-Lozada, L.G., Rivard, C.J., Bjornstad, P.S., Merriman, T., et al. Fat storage syndrome in Pacific peoples: a combination of environment and genetics?. Pac Health Dialog 20 (2014), 11–16.
5. Macdonald, I., Influence of fructose and glucose on serum lipid levels in men and pre- and postmenopausal women. Am J Clin Nutr 18 (1966), 369–372.
6. al-Nagdy, S., Miller, D.S., Yudkin, J., Changes in body composition and metabolism induced by sucrose in the rat. Nutr Metab 12 (1970), 193–219.
7. Laube, H., Klor, H.U., Fussganger, R., Pfeiffer, E.F., The effect of starch, sucrose, glucose and fructose on lipid metabolism in rats. Nutr Metab 15 (1973), 273–280.
8. Maruhama, Y., Macdonald, I., Incorporation of orally administered glucose-U-14C and fructose-U-14C into the triglyceride of liver, plasma, and adipose tissue of rats. Metabolism 22 (1973), 1205–1215.
9. Nikkila, E.A., Control of plasma and liver triglyceride kinetics by carbohydrate metabolism and insulin. Adv Lipid Res 7 (1969), 63–134.
10. Sun, S.Z., Empie, M.W., Fructose metabolism in humans - what isotopic tracer studies tell us. Nutr Metab, 9, 2012, 89.
11. Ouyang, X., Cirillo, P., Sautin, Y., McCall, S., Bruchette, J.L., Diehl, A.M., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 48 (2008), 993–999.
12. Vos, M.B., Lavine, J.E., Dietary fructose in nonalcoholic fatty liver disease. Hepatology 57 (2013), 2525–2531.
13. Lim, J.S., Mietus-Snyder, M., Valente, A., Schwarz, J.M., Lustig, R.H., The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 7 (2010), 251–264.
14. Stanhope, K.L., Schwarz, J.M., Havel, P.J., Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. Curr Opin Lipidol 24 (2013), 198–206.
15. Le, K.A., Tappy, L., Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 9 (2006), 469–475.
16. Lanaspa, M.A., Cicerchi, C., Garcia, G., Li, N., Roncal-Jimenez, C.A., Rivard, C.J., et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PLoS One, 7, 2012, e48801.
17. Lanaspa, M.A., Sanchez-Lozada, L.G., Choi, Y.J., Cicerchi, C., Kanbay, M., Roncal-Jimenez, C.A., et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 287 (2012), 40732–40744.
18. Harley, G., Remarks on diabetes and gout in their relationship to liver disease, with hints regarding their scientific treatment. Br Med J 1 (1893), 1097–1101.
19. Frankel, J.J., Asbury, C.E. Jr., Baker, L.A., Hepatic insufficiency and cirrhosis in diabetes mellitus. AMA Arch Intern Med 86 (1950), 376–390.
20. Ludwig, J., Viggiano, T.R., McGill, D.B., Oh, B.J., Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980), 434–438.
21. Spech, H.J., Liehr, H., Mitschke, H., Nonalcoholic fatty liver hepatitis and fatty cirrhosis mimicking alcoholic liver diseases. Z Gastroenterol 21 (1983), 651–659.
22. Diehl, A.M., Goodman, Z., Ishak, K.G., Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 95 (1988), 1056–1062.
23. Paschos, P., Paletas, K., Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13 (2009), 9–19.
24. Calzadilla Bertot, L., Adams, L.A., The natural course of non-alcoholic fatty liver disease. Int J Mol Sci, 17, 2016.
25. Ray, K., NAFLD-the next global epidemic. Nat Rev Gastroenterol Hepatol, 10, 2013, 621.
26. Mosca, A., Della Corte, C., Sartorelli, M.R., Ferretti, F., Nicita, F., Vania, A., et al. Beverage consumption and paediatric NAFLD. Eat Weight Disord 21 (2016), 581–588.
27. Love-Osborne, K.A., Nadeau, K.J., Sheeder, J., Fenton, L.Z., Zeitler, P., Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. J Adolesc Health 42 (2008), 543–548.
28. Brumbaugh, D.E., Tearse, P., Cree-Green, M., Fenton, L.Z., Brown, M., Scherzinger, A., et al. Intrahepatic fat is increased in the neonatal offspring of obese women with gestational diabetes. J Pediatr 162 (2013), 930–936 e1.
29. Ventura, E.E., Davis, J.N., Goran, M.I., Sugar content of popular sweetened beverages based on objective laboratory analysis: focus on fructose content. Obesity 19 (2011), 868–874.
30. Bruckdorfer, K.R., Khan, I.H., Yudkin, J., Dietary carbohydrate and fatty acid synthetase activity in rat liver and adipose tissue. Biochem J, 123, 1971, 7P.
31. Ackerman, Z., Oron-Herman, M., Grozovski, M., Rosenthal, T., Pappo, O., Link, G., et al. Fructose-induced fatty liver disease: hepatic effects of blood pressure and plasma triglyceride reduction. Hypertension 45 (2005), 1012–1018.
32. Collison, K.S., Maqbool, Z.M., Inglis, A.L., Makhoul, N.J., Saleh, S.M., Bakheet, R.H., et al. Effect of dietary monosodium glutamate on HFCS-induced hepatic steatosis: expression profiles in the liver and visceral fat. Obesity 18 (2010), 1122–1134.
33. Lanaspa, M.A., Sanchez-Lozada, L.G., Cicerchi, C., Li, N., Roncal-Jimenez, C.A., Ishimoto, T., et al. Uric Acid stimulates fructokinase and accelerates fructose metabolism in the development of Fatty liver. PLoS One, 7, 2012, e47948.
34. Sanchez-Lozada, L.G., Mu, W., Roncal, C., Sautin, Y.Y., Abdelmalek, M., Reungjui, S., et al. Comparison of free fructose and glucose to sucrose in the ability to cause fatty liver. Eur J Nutr 49 (2010), 1–9.
35. Schultz, A., Neil, D., Aguila, M.B., Mandarim-de-Lacerda, C.A., Hepatic adverse effects of fructose consumption independent of overweight/obesity. Int J Mol Sci 14 (2013), 21873–21886.
36. Asgharpour, A., Cazanave, S.C., Pacana, T., Seneshaw, M., Vincent, R., Banini, B.A., et al. A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. J Hepatol 65 (2016), 579–588.
37. Nakagawa, T., Hu, H., Zharikov, S., Tuttle, K.R., Short, R.A., Glushakova, O., et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 290 (2006), F625–F631.
38. Shapiro, A., Mu, W., Roncal, C., Cheng, K.Y., Johnson, R.J., Scarpace, P.J., Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol 295 (2008), R1370–R1375.
39. Shapiro, A., Tumer, N., Gao, Y., Cheng, K.Y., Scarpace, P.J., Prevention and reversal of diet-induced leptin resistance with a sugar-free diet despite high fat content. Br J Nutr 106 (2011), 390–397.
40. Reungjui, S., Roncal, C.A., Mu, W., Srinivas, T.R., Sirivongs, D., Johnson, R.J., et al. Thiazide diuretics exacerbate fructose-induced metabolic syndrome. J Am Soc Nephrol 18 (2007), 2724–2731.
41. Roncal-Jimenez, C.A., Lanaspa, M.A., Rivard, C.J., Nakagawa, T., Sanchez-Lozada, L.G., Jalal, D., et al. Sucrose induces fatty liver and pancreatic inflammation in male breeder rats independent of excess energy intake. Metabolism 60 (2011), 1259–1270.
42. Cydylo, M.A., Davis, A.T., Kavanagh, K., Fatty liver promotes fibrosis in monkeys consuming high fructose. Obesity 25 (2017), 290–293.
43. Bremer, A.A., Stanhope, K.L., Graham, J.L., Cummings, B.P., Wang, W., Saville, B.R., et al. Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes. Clin Transl Sci 4 (2011), 243–252.
44. Lanaspa, M.A., Ishimoto, T., Li, N., Cicerchi, C., Orlicky, D.J., Ruzicky, P., et al. Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun, 4, 2013, 2434.
45. Qiu, L., Lin, J., Xu, F., Gao, Y., Zhang, C., Liu, Y., et al. Inhibition of aldose reductase activates hepatic peroxisome proliferator-activated receptor-alpha and ameliorates hepatosteatosis in diabetic db/db mice. Exp Diabetes Res, 2012, 2012, 789730.
46. Abdelmalek, M.F., Suzuki, A., Guy, C., Unalp-Arida, A., Colvin, R., Johnson, R.J., et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51 (2010), 1961–1971.
47. Collison, K.S., Saleh, S.M., Bakheet, R.H., Al-Rabiah, R.K., Inglis, A.L., Makhoul, N.J., et al. Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. Obesity, 2009.
48. Dekker, M.J., Su, Q., Baker, C., Rutledge, A.C., Adeli, K., Fructose: a highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab 299 (2010), E685–E694.
49. Abdelmalek, M.F., Lazo, M., Horska, A., Bonekamp, S., Lipkin, E.W., Balasubramanyam, A., et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 56 (2012), 952–960.
50. Nomura, K., Yamanouchi, T., The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 23 (2012), 203–208.
51. Mosca, A., Nobili, V., De Vito, R., Crudele, A., Scorletti, E., Villani, A., et al. Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. J Hepatol 66 (2017), 1031–1036.
52. Hamza, R.T., Ahmed, A.Y., Rezk, D.G., Hamed, A.I., Dietary fructose intake in obese children and adolescents: relation to procollagen type III N-terminal peptide (P3NP) and non-alcoholic fatty liver disease. J Pediatr Endocrinol Metab 29 (2016), 1345–1352.
53. O'Sullivan, T.A., Oddy, W.H., Bremner, A.P., Sherriff, J.L., Ayonrinde, O.T., Olynyk, J.K., et al. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr 58 (2014), 624–631.
54. Maersk, M., Belza, A., Stodkilde-Jorgensen, H., Ringgaard, S., Chabanova, E., Thomsen, H., et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr 95 (2012), 283–289.
55. Schwarz, J.M., Noworolski, S.M., Erkin-Cakmak, A., Korn, N.J., Wen, M.J., Tai, V.W., et al. Effects of dietary fructose restriction on liver fat, de novo lipogenesis, and insulin kinetics in children with obesity. Gastroenterology 153 (2017), 743–752.
56. Lustig, R.H., Mulligan, K., Noworolski, S.M., Tai, V.W., Wen, M.J., Erkin-Cakmak, A., et al. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity, 2015.
57. Kanerva, N., Sandboge, S., Kaartinen, N.E., Mannisto, S., Eriksson, J.G., Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr 100 (2014), 1133–1138.
58. Vasdev, S., Gill, V., Parai, S., Longerich, L., Gadag, V., Dietary vitamin E and C supplementation prevents fructose induced hypertension in rats. Mol Cell Biochem 241 (2002), 107–114.
59. Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol, 6, 2006, 33.
60. Ruhl, C.E., Everhart, J.E., Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey. Aliment Pharmacol Ther 41 (2015), 65–76.
61. An, R., Prevalence and trends of adult obesity in the US, 1999–2012. ISRN Obes, 2014, 2014, 185132.
62. Flegal, K.M., Carroll, M.D., Kuczmarski, R.J., Johnson, C.L., Overweight and obesity in the United States: prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 22 (1998), 39–47.
63. Softic, S., Cohen, D.E., Kahn, C.R., Role of dietary fructose and hepatic de novo lipogenesis in fatty liver disease. Dig Dis Sci 61 (2016), 1282–1293.
64. Faeh, D., Minehira, K., Schwarz, J.M., Periasamy, R., Park, S., Tappy, L., Effect of fructose overfeeding and fish oil administration on hepatic de novo lipogenesis and insulin sensitivity in healthy men. Diabetes 54 (2005), 1907–1913.
65. Stanhope, K.L., Schwarz, J.M., Keim, N.L., Griffen, S.C., Bremer, A.A., Graham, J.L., et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 119 (2009), 1322–1334.
66. Cox, C.L., Stanhope, K.L., Schwarz, J.M., Graham, J.L., Hatcher, B., Griffen, S.C., et al. Consumption of fructose-sweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women. Eur J Clin Nutr 66 (2012), 201–208.
67. Schwarz, J.M., Acheson, K.J., Tappy, L., Piolino, V., Muller, M.J., Felber, J.P., et al. Thermogenesis and fructose metabolism in humans. Am J Physiol 262 (1992), E591–E598.
68. Mizobe, T., Nakajima, Y., Ueno, H., Sessler, D.I., Fructose administration increases intraoperative core temperature by augmenting both metabolic rate and the vasoconstriction threshold. Anesthesiology 104 (2006), 1124–1130.
69. Steinmann, B., Gitzelmann, R., Van den Berghe, G., Disorders of fructose metabolism. Scriver, C., Beaudet, A., Sly, W., Valle, D., (eds.) The metabolic and molecular basis of inherited disease, 2001, McGraw-Hill, New York, 1489–1520.
70. Maenpaa, P.H., Raivio, K.O., Kekomaki, M.P., Liver adenine nucleotides: fructose-induced depletion and its effect on protein synthesis. Science 161 (1968), 1253–1254.
71. Smith, C.M., Rovamo, L.M., Raivio, K.O., Fructose-induced adenine nucleotide catabolism in isolated rat hepatocytes. Can J Biochem 55 (1977), 1237–1240.
72. van den Berghe, G., Bronfman, M., Vanneste, R., Hers, H.G., The mechanism of adenosine triphosphate depletion in the liver after a load of fructose. A kinetic study of liver adenylate deaminase. Biochem J 162 (1977), 601–609.
73. Kurtz, T.W., Kabra, P.M., Booth, B.E., Al-Bander, H.A., Portale, A.A., Serena, B.G., et al. Liquid-chromatographic measurements of inosine, hypoxanthine, and xanthine in studies of fructose-induced degradation of adenine nucleotides in humans and rats. Clin Chem 32 (1986), 782–786.
74. Van den Berghe, G., Fructose: metabolism and short-term effects on carbohydrate and purine metabolic pathways. Prog Biochem Pharmacol 21 (1986), 1–32.
75. Emmerson, B.T., Effect of oral fructose on urate production. Ann Rheum Dis 33 (1974), 276–280.
76. Raivio, K.O., Becker, A., Meyer, L.J., Greene, M.L., Nuki, G., Seegmiller, J.E., Stimulation of human purine synthesis de novo by fructose infusion. Metabolism 24 (1975), 861–869.
77. Cortez-Pinto, H., Chatham, J., Chacko, V.P., Arnold, C., Rashid, A., Diehl, A.M., Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282 (1999), 1659–1664.
78. Nair, S., P Chacko, V., Arnold, C., Diehl, A.M., Hepatic ATP reserve and efficiency of replenishing: comparison between obese and nonobese normal individuals. Am J Gastroenterol 98 (2003), 466–470.
79. Bawden, S.J., Stephenson, M.C., Ciampi, E., Hunter, K., Marciani, L., Macdonald, I.A., et al. Investigating the effects of an oral fructose challenge on hepatic ATP reserves in healthy volunteers: A P MRS study. Clin Nutr, 2015.
80. Perheentupa, J., Raivio, K., Fructose-induced hyperuricaemia. Lancet 2 (1967), 528–531.
81. Stirpe, F., Della Corte, E., Bonetti, E., Abbondanza, A., Abbati, A., De Stefano, F., Fructose-induced hyperuricaemia. Lancet 2 (1970), 1310–1311.
82. Le, M.T., Frye, R.F., Rivard, C.J., Cheng, J., McFann, K.K., Segal, M.S., et al. Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. Metabolism 61 (2012), 641–651.
83. Choi, Y.J., Shin, H.S., Choi, H.S., Park, J.W., Jo, I., Oh, E.S., et al. Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. Lab Invest 94 (2014), 1114–1125.
84. Diggle, C.P., Shires, M., McRae, C., Crellin, D., Fisher, J., Carr, I.M., et al. Both isoforms of ketohexokinase are dispensable for normal growth and development. Physiol Genomics 42a (2010), 235–243.
85. Ishimoto, T., Lanaspa, M.A., Le, M.T., Garcia, G.E., Diggle, C.P., Maclean, P.S., et al. Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice. Proc Natl Acad Sci U S A 109 (2012), 4320–4325.
86. Softic, S., Gupta, M.K., Wang, G.X., Fujisaka, S., O'Neill, B.T., Rao, T.N., et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J Clin Invest, 2017.
87. Johnson, R.J., Rivard, C., Lanaspa, M.A., Otabachian-Smith, S., Ishimoto, T., Cicerchi, C., et al. Fructokinase, fructans, intestinal permeability, and metabolic syndrome: an equine connection?. J Equine Vet Sci 33 (2013), 120–126.
88. Bergheim, I., Weber, S., Vos, M., Kramer, S., Volynets, V., Kaserouni, S., et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 48 (2008), 983–992.
89. Spruss, A., Bergheim, I., Dietary fructose and intestinal barrier: potential risk factor in the pathogenesis of nonalcoholic fatty liver disease. J Nutr Biochem 20 (2009), 657–662.
90. Thuy, S., Ladurner, R., Volynets, V., Wagner, S., Strahl, S., Konigsrainer, A., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 138 (2008), 1452–1455.
91. Jin, R., Willment, A., Patel, S.S., Sun, X., Song, M., Mannery, Y.O., et al. Fructose induced endotoxemia in pediatric nonalcoholic Fatty liver disease. Int J Hepatol, 2014, 2014, 560620.
92. Jegatheesan, P., Beutheu, S., Freese, K., Waligora-Dupriet, A.J., Nubret, E., Butel, M.J., et al. Preventive effects of citrulline on Western diet-induced non-alcoholic fatty liver disease in rats. Br J Nutr 116 (2016), 191–203.
93. Jegatheesan, P., Beutheu, S., Ventura, G., Sarfati, G., Nubret, E., Kapel, N., et al. Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease. Clin Nutr 35 (2016), 175–182.
94. Ritze, Y., Bardos, G., Claus, A., Ehrmann, V., Bergheim, I., Schwiertz, A., et al. Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice. PLoS One, 9, 2014, e80169.
95. Arrese, M., Cabrera, D., Kalergis, A.M., Feldstein, A.E., Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci 61 (2016), 1294–1303.
96. Bhattacharjee, J., Kumar, J.M., Arindkar, S., Das, B., Pramod, U., Juyal, R.C., et al. Role of immunodeficient animal models in the development of fructose induced NAFLD. J Nutr Biochem 25 (2014), 219–226.
97. Cox, C.L., Stanhope, K.L., Schwarz, J.M., Graham, J.L., Hatcher, B., Griffen, S.C., et al. Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans. Nutr Metab, 9, 2012, 68.
98. Reiser, S., Powell, A.S., Scholfield, D.J., Panda, P., Ellwood, K.C., Canary, J.J., Blood lipids, lipoproteins, apoproteins, and uric acid in men fed diets containing fructose or high-amylose cornstarch. Am J Clin Nutr 49 (1989), 832–839.
99. Choi, J.W., Ford, E.S., Gao, X., Choi, H.K., Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The third national health and nutrition examination survey. Arthritis Rheum 59 (2007), 109–116.
100. Choi, H.K., Curhan, G., Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 336 (2008), 309–312.
101. Baldwin, W., McRae, S., Marek, G., Wymer, D., Pannu, V., Baylis, C., et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 60 (2011), 1258–1269.
102. Wang, W., Wang, C., Ding, X.Q., Pan, Y., Gu, T.T., Wang, M.X., et al. Quercetin and allopurinol reduce liver thioredoxin-interacting protein to alleviate inflammation and lipid accumulation in diabetic rats. Br J Pharmacol 169 (2013), 1352–1371.
103. Nakatsu, Y., Seno, Y., Kushiyama, A., Sakoda, H., Fujishiro, M., Katasako, A., et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol 309 (2015), G42–G51.
104. Kono, H., Rusyn, I., Bradford, B.U., Connor, H.D., Mason, R.P., Thurman, R.G., Allopurinol prevents early alcohol-induced liver injury in rats. J Pharmacol Exp Ther 293 (2000), 296–303.
105. Tapia, E., Cristobal, M., Garcia-Arroyo, F.E., Soto, V., Monroy-Sanchez, F., Pacheco, U., et al. Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats. Am J Physiol Renal Physiol 304 (2013), F727–F736.
106. Addabbo, F., Montagnani, M., Goligorsky, M.S., Mitochondria and reactive oxygen species. Hypertension 53 (2009), 885–892.
107. Addabbo, F., Ratliff, B., Park, H.C., Kuo, M.C., Ungvari, Z., Csiszar, A., et al. The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: proteomic approach. Am J Pathol 174 (2009), 34–43.
108. Herman, M.A., Samuel, V.T., The sweet path to metabolic demise: fructose and lipid synthesis. Trends Endocrinol Metab 27 (2016), 719–730.
109. Miyazaki, M., Dobrzyn, A., Man, W.C., Chu, K., Sampath, H., Kim, H.J., et al. Stearoyl-CoA desaturase 1 gene expression is necessary for fructose-mediated induction of lipogenic gene expression by sterol regulatory element-binding protein-1c-dependent and -independent mechanisms. J Biol Chem 279 (2004), 25164–25171.
110. Nagai, Y., Yonemitsu, S., Erion, D.M., Iwasaki, T., Stark, R., Weismann, D., et al. The role of peroxisome proliferator-activated receptor gamma coactivator-1 beta in the pathogenesis of fructose-induced insulin resistance. Cell Metab 9 (2009), 252–264.
111. Koo, H.Y., Miyashita, M., Cho, B.H., Nakamura, M.T., Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochem Biophys Res Commun 390 (2009), 285–289.
112. Kim, M.S., Krawczyk, S.A., Doridot, L., Fowler, A.J., Wang, J.X., Trauger, S.A., et al. ChREBP regulates fructose-induced glucose production independently of insulin signaling. J Clin Invest 126 (2016), 4372–4386.
113. Cicerchi, C., Li, N., Kratzer, J., Garcia, G., Roncal-Jimenez, C.A., Tanabe, K., et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. FASEB J 28 (2014), 3339–3350.
114. Wan, X., Xu, C., Lin, Y., Lu, C., Li, D., Sang, J., et al. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol 64 (2016), 925–932.
115. Kanellis, J., Watanabe, S., Li, J.H., Kang, D.H., Li, P., Nakagawa, T., et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41 (2003), 1287–1293.
116. Sirota, J.C., McFann, K., Targher, G., Johnson, R.J., Chonchol, M., Jalal, D.I., Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 62 (2013), 392–399.
117. Sartorio, A., Del Col, A., Agosti, F., Mazzilli, G., Bellentani, S., Tiribelli, C., et al. Predictors of non-alcoholic fatty liver disease in obese children. Eur J Clin Nutr 61 (2007), 877–883.
118. Vos, M.B., Colvin, R., Belt, P., Molleston, J.P., Murray, K.F., Rosenthal, P., et al. Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD. J Pediatr Gastroenterol Nutr 54 (2012), 90–96.
119. Sullivan, J.S., Le, M.T., Pan, Z., Rivard, C., Love-Osborne, K., Robbins, K., et al. Oral fructose absorption in obese children with non-alcoholic fatty liver disease. Pediatr Obes 10 (2015), 188–195.
120. Li, Y., Xu, C., Yu, C., Xu, L., Miao, M., Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol 50 (2009), 1029–1034.
121. Kuo, C.F., Yu, K.H., Luo, S.F., Chiu, C.T., Ko, Y.S., Hwang, J.S., et al. Gout and risk of non-alcoholic fatty liver disease. Scand J Rheumatol 39 (2010), 466–471.
122. Petta, S., Camma, C., Cabibi, D., Di Marco, V., Craxi, A., Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 34 (2011), 757–766.
123. Lee, J.W., Cho, Y.K., Ryan, M., Kim, H., Lee, S.W., Chang, E., et al. Serum uric Acid as a predictor for the development of nonalcoholic Fatty liver disease in apparently healthy subjects: a 5-year retrospective cohort study. Gut Liver 4 (2010), 378–383.
124. Xu, C., Yu, C., Xu, L., Miao, M., Li, Y., High serum uric acid increases the risk for nonalcoholic Fatty liver disease: a prospective observational study. PLoS One, 5, 2010, e11578.
125. Liu, Z., Que, S., Zhou, L., Zheng, S., Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies. Sci Rep, 5, 2015, 14325.
126. Zhou, Y., Wei, F., Fan, Y., High serum uric acid and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clin Biochem 49 (2016), 636–642.
127. Kim, H.J., Lee, K.E., Kim, D.J., Kim, S.K., Ahn, C.W., Lim, S.K., et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 164 (2004), 2169–2175.
128. Sertoglu, E., Ercin, C.N., Celebi, G., Gurel, H., Kayadibi, H., Genc, H., et al. The relationship of serum uric acid with non-alcoholic fatty liver disease. Clin Biochem 47 (2014), 383–388.
129. Feldstein, A.E., Wieckowska, A., Lopez, A.R., Liu, Y.C., Zein, N.N., McCullough, A.J., Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 50 (2009), 1072–1078.
130. Sylvia S Sedhom OAB, Salwa H Salama and Mohamad A Mokhles. Assessment of the therapeutic effect of allopurinol in patients with non-alcoholic fatty liver disease associated with hyperuricemia by cytokeratin 18. 9th Euro Global Gastroenterology Conference; Valenica Spain 2016.
131. Johnson, R.J., Nakagawa, T., Sanchez-Lozada, L.G., Shafiu, M., Sundaram, S., Le, M., et al. Sugar, uric Acid, and the etiology of diabetes and obesity. Diabetes 62 (2013), 3307–3315.
132. Ishimoto, T., Lanaspa, M.A., Rivard, C.J., Roncal-Jimenez, C.A., Orlicky, D.J., Cicerchi, C., et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 58 (2013), 1632–1643.
133. 2 emission and cellular redox state link excess fat intake to insulin resistance in both rodents and humans. J Clin Invest 119 (2009), 573–581.
134. Alwahsh, S.M., Xu, M., Schultze, F.C., Wilting, J., Mihm, S., Raddatz, D., et al. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. PLoS One, 9, 2014, e104220.
135. Hu, G., Jousilahti, P., Peltonen, M., Lindstrom, J., Tuomilehto, J., Urinary sodium and potassium excretion and the risk of type 2 diabetes: a prospective study in Finland. Diabetologia 48 (2005), 1477–1483.
136. Ma, Y., He, F.J., MacGregor, G.A., High salt intake: independent risk factor for obesity?. Hypertension 66 (2015), 843–849.
137. Huh, J.H., Lee, K.J., Lim, J.S., Lee, M.Y., Park, H.J., Kim, M.Y., et al. High dietary sodium intake assessed by estimated 24-h urinary sodium excretion is associated with NAFLD and hepatic fibrosis. PLoS One, 10, 2015, e0143222.
138. Davis, J.N., Le, K.A., Walker, R.W., Vikman, S., Spruijt-Metz, D., Weigensberg, M.J., et al. Increased hepatic fat in overweight Hispanic youth influenced by interaction between genetic variation in PNPLA3 and high dietary carbohydrate and sugar consumption. Am J Clin Nutr 92 (2010), 1522–1527.
139. Nobili, V., Liccardo, D., Bedogni, G., Salvatori, G., Gnani, D., Bersani, I., et al. Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes Nutr, 9, 2014, 392.
140. Sevastianova, K., Kotronen, A., Gastaldelli, A., Perttila, J., Hakkarainen, A., Lundbom, J., et al. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. Am J Clin Nutr 94 (2011), 104–111.
141. Simopoulos, A.P., Dietary omega-3 fatty acid deficiency and high fructose intake in the development of metabolic syndrome, brain metabolic abnormalities, and non-alcoholic fatty liver disease. Nutrients 5 (2013), 2901–2923.
142. Vauzour, D., Rodriguez-Ramiro, I., Rushbrook, S., Ipharraguerre, I.R., Bevan, D., Davies, S., et al. N-3 Fatty acids combined with flavan-3-ols prevent steatosis and liver injury in a murine model of NAFLD. Biochim Biophys Acta 1864 (2017), 69–78.
143. Bremer, A.A., Stanhope, K.L., Graham, J.L., Cummings, B.P., Ampah, S.B., Saville, B.R., et al. Fish oil supplementation ameliorates fructose-induced hypertriglyceridemia and insulin resistance in adult male rhesus macaques. J Nutr 144 (2014), 5–11.
144. Hu, Q.H., Zhang, X., Pan, Y., Li, Y.C., Kong, L.D., Allopurinol, quercetin and rutin ameliorate renal NLRP3 inflammasome activation and lipid accumulation in fructose-fed rats. Biochem Pharmacol 84 (2012), 113–125.
145. Gutierrez-Salmean, G., Meaney, E., Lanaspa, M.A., Cicerchi, C., Johnson, R.J., Dugar, S., et al. A randomized, placebo-controlled, double-blind study on the effects of (-)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects. Int J Cardiol 223 (2016), 500–506.
146. Korieh, A., Crouzoulon, G., Dietary regulation of fructose metabolism in the intestine and in the liver of the rat. Duration of the effects of a high fructose diet after the return to the standard diet. Arch Int Physiol Biochim Biophys 99 (1991), 455–460.
147. Rumessen, J.J., Gudmand-Hoyer, E., Absorption capacity of fructose in healthy adults. Comparison with sucrose and its constituent monosaccharides. Gut 27 (1986), 1161–1168.
148. Jin, R., Le, N.A., Liu, S., Farkas Epperson, M., Ziegler, T.R., Welsh, J.A., et al. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab 97 (2012), E1088–E1098.
149. Zhang, Y., Hong, Q., Huang, Z., Xue, P., Lv, Y., Fu, B., et al. ALDR enhanced endothelial injury in hyperuricemia screened using SILAC. Cell Physiol Biochem 33 (2014), 479–490.
150. Huang, Z., Hong, Q., Zhang, X., Xiao, W., Wang, L., Cui, S., et al. Aldose reductase mediates endothelial cell dysfunction induced by high uric acid concentrations. Cell Commun Signal, 15, 2017, 3.
151. Radi, R., Tan, S., Prodanov, E., Evans, R.A., Parks, D.A., Inhibition of xanthine oxidase by uric acid and its influence on superoxide radical production. Biochim Biophys Acta 1122 (1992), 178–182.
152. Tan, S., Radi, R., Gaudier, F., Evans, R.A., Rivera, A., Kirk, K.A., et al. Physiologic levels of uric acid inhibit xanthine oxidase in human plasma. Pediatr Res 34 (1993), 303–307.
153. Chiu, S., Sievenpiper, J.L., de Souza, R.J., Cozma, A.I., Mirrahimi, A., Carleton, A.J., et al. Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials. Eur J Clin Nutr 68 (2014), 416–423.
154. Chung, M., Ma, J., Patel, K., Berger, S., Lau, J., Lichtenstein, A.H., Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: a systematic review and meta-analysis. Am J Clin Nutr 100 (2014), 833–849.
155. Schillinger, D., Tran, J., Mangurian, C., Kearns, C., Do sugar-sweetened beverages cause obesity and diabetes? Industry and the manufacture of scientific controversy. Ann Intern Med 165 (2016), 895–897.
156. Bes-Rastrollo, M., Schulze, M.B., Ruiz-Canela, M., Martinez-Gonzalez, M.A., Financial conflicts of interest and reporting bias regarding the association between sugar-sweetened beverages and weight gain: a systematic review of systematic reviews. PLoS Med, 10, 2013, e1001578.
157. Garcia-Ruiz, I., Rodriguez-Juan, C., Diaz-Sanjuan, T., del Hoyo, P., Colina, F., Munoz-Yague, T., et al. Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 44 (2006), 581–591.
158. Yu, M.A., Sanchez-Lozada, L.G., Johnson, R.J., Kang, D.H., Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens 28 (2010), 1234–1242.
159. Dushay, J.R., Toschi, E., Mitten, E.K., Fisher, F.M., Herman, M.A., Maratos-Flier, E., Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab 4 (2015), 51–57.
160. Fisher, F.M., Kim, M., Doridot, L., Cunniff, J.C., Parker, T.S., Levine, D.M., et al. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol Metab 6 (2017), 14–21.
161. Johnston, R.D., Stephenson, M.C., Crossland, H., Cordon, S.M., Palcidi, E., Cox, E.F., et al. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology 145 (2013), 1016–1025 e2.
162. Aeberli, I., Hochuli, M., Gerber, P.A., Sze, L., Murer, S.B., Tappy, L., et al. Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial. Diabetes Care 36 (2013), 150–156.
163. Lecoultre, V., Egli, L., Carrel, G., Theytaz, F., Kreis, R., Schneiter, P., et al. Effects of fructose and glucose overfeeding on hepatic insulin sensitivity and intrahepatic lipids in healthy humans. Obesity 21 (2013), 782–785.
164. Silbernagel, G., Machann, J., Unmuth, S., Schick, F., Stefan, N., Haring, H.U., et al. Effects of 4-week very-high-fructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: an exploratory trial. Br J Nutr 106 (2011), 79–86.
165. Schwarz, J.M., Noworolski, S.M., Wen, M.J., Dyachenko, A., Prior, J.L., Weinberg, M.E., et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. J Clin Endocrinol Metab 100 (2015), 2434–2442.